Treatment Guide

Treatment for Separation Anxiety: Therapy, Drugs and the Evidence

CBT is the first-line treatment for separation anxiety. In a 2008 trial, 80.7% of kids improved with CBT plus sertraline vs. 23.7% on placebo.

Mental Health Stats Research Team 7 min read

Key Takeaways

  • The American Academy of Child and Adolescent Psychiatry's 2020 guideline recommends cognitive behavioral therapy (CBT) for patients 6 to 18 years old with separation anxiety disorder and treats it as the first-line option for mild to moderate cases[1].Ages 6-18[1]
  • In the 2008 CAMS trial of 488 children and teens, 80.7% improved with CBT plus sertraline, compared with 59.7% on CBT alone, 54.9% on sertraline alone and 23.7% on placebo[2].80.7%[2]
  • A 2020 Cochrane review of 87 studies found that 541 per 1,000 young people lost their primary anxiety diagnosis after CBT, versus 178 per 1,000 on a waitlist[3].54.1% vs. 17.8%[3]
  • No medication has an FDA-labeled indication for separation anxiety disorder, so SSRIs and SNRIs prescribed for it are used off-label[4].0 labeled drugs[4]
  • A parent-only program, SPACE, was noninferior to child-focused CBT in a 2020 trial of 124 children aged 7 to 14[5].124 children[5]
  • Gains do not always hold: in long-term follow-up of CAMS, about 22% of participants were in stable remission, 48% had relapsed at some point and 30% stayed chronically ill[6].22%[6]

Treatment for Separation Anxiety: What Guidelines Recommend

Treatment for separation anxiety disorder starts with cognitive behavioral therapy (CBT), with an SSRI antidepressant added or substituted when symptoms are more severe. That is the position of the American Academy of Child and Adolescent Psychiatry (AACAP), whose 2020 guideline covers separation anxiety disorder in patients 6 to 18 years old[1].

The guideline makes four treatment statements that name separation anxiety. It recommends CBT (grade 1C) and SSRIs (grade 1B), and suggests that combined CBT and an SSRI could be offered ahead of either alone (2C) and that SNRIs could be offered (2C)[1].

It describes CBT as the first-line choice "particularly for mild to moderate presentations," with medication as the alternative for more severe cases or when quality CBT is unavailable[1].

Most of the evidence behind these statements comes from trials that enrolled children with separation, generalized or social anxiety together. How common the disorder is, and in whom, is covered on the separation anxiety disorder statistics page; this article covers what treatment involves and how well it works.

Separation anxiety disorder

An anxiety disorder marked by developmentally inappropriate, excessive anxiety about separation from the people a person is most attached to. DSM-5-TR requires at least 3 of 8 listed symptoms, such as refusing to sleep away from an attachment figure or repeated physical complaints when separation is expected, lasting at least 4 weeks in children and adolescents and typically 6 months or more in adults[4].

Related Terms

adult separation anxiety disorder
family accommodation
school refusal
graduated exposure

Source: DSM-5-TR criteria via StatPearls (NCBI Bookshelf)

How CBT for Separation Anxiety Works

CBT for anxiety targets three dimensions: anxious thoughts, avoidance and physical arousal[1]. Sessions follow an agenda with homework so that skills carry over to home and school, and AACAP sets the goal as meaningful improvement within 12 to 20 sessions[1].

The core technique is graduated exposure. The child and therapist build a fear hierarchy and master it step by step, and the guideline calls this "the cornerstone of treatment" for situation-driven anxiety such as separation anxiety[1].

For younger children, exposure is adapted with real-life practice, stories, a therapist modeling calm behavior and rewards for brave steps[1]. Exposure is calibrated to the individual child, much as a medication dose is adjusted[1].

Parents usually take part. AACAP notes that family-directed work, such as reducing parental anxiety and teaching anxiety-reducing parenting skills, often supplements a child's individual treatment[1].

One of the few trials built specifically for this disorder tested a 16-session program that combined parent training with standard CBT in 43 children aged 5 to 7[7]. At a 4-week follow-up, 76.2% of treated children no longer met DSM-IV criteria for separation anxiety disorder, compared with 13.6% on a waiting list[7].

What Trials Show for Therapy, Medication and Both

The largest head-to-head study is the Child/Adolescent Anxiety Multimodal Study (CAMS), published in 2008[2]. It randomized 488 children aged 7 to 17 with a primary diagnosis of separation anxiety disorder, generalized anxiety disorder or social phobia to 14 sessions of CBT, sertraline, both, or a placebo pill for 12 weeks[2].

On a clinician-rated improvement scale, 80.7% of the combination group were much or very much improved, against 59.7% with CBT, 54.9% with sertraline and 23.7% with placebo[2]. All three active treatments outperformed placebo[2].

Pooled data support therapy on its own. The 2020 Cochrane review of CBT for childhood anxiety included 87 studies and 5,964 participants[3]. Against a waitlist, CBT raised remission of the primary anxiety diagnosis from 178 to 541 per 1,000 (odds ratio 5.45, moderate-quality evidence)[3].

The comparison with usual care was less clear. Remission was 687 per 1,000 with CBT versus 408 per 1,000 with treatment as usual, but the confidence interval included no effect and the evidence was rated low quality[3].

Results From Key Separation Anxiety Treatment Studies

StudyParticipantsTreatmentResult
CAMS (2008)488 youth, ages 7-17CBT + sertraline80.7% much improved
CAMS (2008)488 youth, ages 7-17CBT alone59.7% much improved
CAMS (2008)488 youth, ages 7-17Sertraline alone54.9% much improved
CAMS (2008)488 youth, ages 7-17Placebo23.7% much improved
Schneider et al. (2011)43 children, ages 5-716-session SAD-specific CBT76.2% vs. 13.6% waitlist free of diagnosis
Cochrane review (2020)39 trials, 2,697 youthCBT vs. waitlist54.1% vs. 17.8% remission

Response and remission in the largest mixed-anxiety trial, a separation anxiety-specific trial and a Cochrane meta-analysis[2][7][3].

1CAMS measured response on the Clinical Global Impression-Improvement scale and enrolled youth with separation, generalized or social anxiety. The other rows measure loss of the anxiety diagnosis[2][3].

Sources

  • •NEJM, 2008
  • •Psychotherapy and Psychosomatics, 2011
  • •Cochrane, 2020
Children and teens much or very much improved after 12 weeks of CBT plus sertraline (CAMS)
80.7%

Combined treatment beat CBT alone (59.7%), sertraline alone (54.9%) and placebo (23.7%) in the largest trial that included separation anxiety disorder<sup class="citation-ref" data-citation-hash="cite-walkupjtalba" data-source="New England Journal of Medicine" data-year="2008" data-url="https://www.nejm.org/doi/full/10.1056/NEJMoa0804633" data-ama="Walkup JT, Albano AM, Piacentini J, et al. Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety. New England Journal of Medicine. Published 2008. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa0804633"><a href="#sources">[2]</a></sup>.

"80.7% for combination therapy"

New England Journal of Medicine(2008) View Source

Medication for Separation Anxiety: SSRIs, SNRIs and What Is Not Recommended

No medication has an FDA-labeled indication for separation anxiety disorder, so drugs prescribed for it are used off-label[4]. SSRIs are the first-line medication class for children, and clinicians may also prescribe SNRIs[4].

FDA labeling has shifted since AACAP's 2020 guideline, which noted that no specific SSRI had FDA approval for pediatric anxiety[1]. The escitalopram label, revised in May 2023, now covers generalized anxiety disorder in patients 7 years and older[8].

Duloxetine, an SNRI, is labeled for generalized anxiety disorder in children and adolescents aged 7 to 17[1]. Neither label covers separation anxiety disorder.

Every SSRI carries an FDA boxed warning for suicidal thinking and behavior through age 24[1]. The escitalopram label directs clinicians to monitor for clinical worsening and new suicidal thoughts, especially in the first few months of treatment and after dose changes[8].

On duration, AACAP describes a generally accepted approach of continuing an effective, tolerated dose for about 12 months after remission, then stopping during a relatively low-stress period while monitoring for symptoms returning[1].

Benzodiazepines and tricyclic antidepressants are not recommended for childhood anxiety disorders because the evidence for them is insufficient or low quality[4]. Drug-by-drug comparisons are covered in SSRIs for anxiety and anxiety medication.

How to read these numbers: The largest trials pooled separation anxiety disorder with generalized and social anxiety disorders, so their response rates describe childhood anxiety treatment broadly[2]. Trials limited to separation anxiety are small, and the one randomized drug trial in adults found for this article enrolled 24 people[9].

Parent-Led Treatment and Options for Young Children

Researchers use the term family accommodation for the ways parents adjust their own behavior around a child's anxiety, and research implicates it in the maintenance and course of childhood anxiety[5].

Supportive Parenting for Anxious Childhood Emotions (SPACE) treats the child entirely through the parents, with no direct contact between child and therapist[5]. In a 2020 noninferiority trial of 124 children aged 7 to 14 with primary anxiety disorders, SPACE was noninferior to child-focused CBT, and it reduced family accommodation more[5].

Parent-only treatment also offers a route for children who are unable or unwilling to take part in therapy themselves[4].

AACAP's treatment recommendations cover ages 6 to 18, leaving preschoolers outside their scope[1]. The CALM Program is an anxiety-focused adaptation of parent-child interaction therapy (PCIT); its name stands for Coaching Approach behavior and Leading by Modeling[10]. Related approaches for this age group are reviewed in play therapy.

CALM's first pilot was small: 9 children aged 4 to 8, of whom roughly 80% completed all sessions and every completer was rated a treatment responder[10]. That is a feasibility signal, not proof of efficacy.

Treatment for Separation Anxiety in Adults

DSM-5 recognized separation anxiety disorder as a diagnosis in adults[9]. In adults, symptoms typically last 6 months or more before diagnosis[4].

Treatment evidence for adults is thin. A 2017 pilot randomized 24 adults to 12 weeks of the antidepressant vilazodone or placebo[9]. Response rates at week 12 did not differ significantly between groups, though the vilazodone group improved more on a structured separation anxiety symptom interview[9].

The authors concluded that vilazodone may have efficacy and warrants further study[9]. Beyond that pilot, this review found no large randomized trial of a treatment designed for adult separation anxiety disorder. Evidence on CBT for adult anxiety in general is covered in therapy for anxiety.

How Long Treatment Takes and Whether Gains Last

Acute treatment in trials is short: 12 weeks in CAMS[2] and 16 sessions in the disorder-specific trial for young children[7]. AACAP's stated goal for structured CBT is meaningful improvement within 12 to 20 sessions[1].

Long-term follow-up is less reassuring. The CAMELS study assessed 319 former CAMS participants every year for 4 years, starting 4 to 12 years after treatment[6]. Almost 22% were in stable remission, 30% were chronically ill and 48% had relapsed at some point[6].

The type of treatment a child received was not associated with long-term remission status[6]. Children who responded during acute treatment were less likely to end up in the chronically ill group, which the authors read as a sign that early response may reduce the risk of chronic anxiety[6].

Those figures cover separation, social and generalized anxiety together; this review found no long-term follow-up of comparable size for separation anxiety alone. For anxiety across all ages, see the anxiety overview.

Frequently Asked Questions

Sources & References

  1. Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. Journal of the American Academy of Child & Adolescent Psychiatry. Published 2020. Accessed October 2026. https://www.jaacap.org/article/S0890-8567(20)30280-X/fulltext [Link]
  2. Walkup JT, Albano AM, Piacentini J, et al. Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety. New England Journal of Medicine. Published 2008. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa0804633 [Link]
  3. James AC, Reardon T, Soler A, James G, Creswell C. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews. Published 2020. Accessed October 2026. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013162.pub2/full [Link]
  4. Feriante J, Torrico TJ, McArthur J, Bernstein B. Separation Anxiety Disorder. StatPearls Publishing, NCBI Bookshelf. Published 2026. Accessed October 2026. https://www.ncbi.nlm.nih.gov/books/NBK560793/ [Link]
  5. Lebowitz ER, Marin C, Martino A, Shimshoni Y, Silverman WK. Parent-Based Treatment as Efficacious as Cognitive-Behavioral Therapy for Childhood Anxiety: A Randomized Noninferiority Study of Supportive Parenting for Anxious Childhood Emotions. Journal of the American Academy of Child & Adolescent Psychiatry. Published 2020. Accessed October 2026. https://doi.org/10.1016/j.jaac.2019.02.014 [Link]
  6. Ginsburg GS, Becker-Haimes EM, Keeton C, et al. Results From the Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes. Journal of the American Academy of Child & Adolescent Psychiatry. Published 2018. Accessed October 2026. https://doi.org/10.1016/j.jaac.2018.03.017 [Link]
  7. Schneider S, Blatter-Meunier J, Herren C, Adornetto C, In-Albon T, Lavallee K. Disorder-Specific Cognitive-Behavioral Therapy for Separation Anxiety Disorder in Young Children: A Randomized Waiting-List-Controlled Trial. Psychotherapy and Psychosomatics. Published 2011. Accessed October 2026. https://doi.org/10.1159/000323444 [Link]
  8. Lexapro (escitalopram) prescribing information, revised 5/2023. U.S. Food and Drug Administration. Published 2023. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s055,021365s039lbl.pdf [Link]
  9. Schneier FR, Moskow DM, Choo TH, Galfalvy H, Campeas R, Sanchez-Lacay A. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. Depression and Anxiety. Published 2017. Accessed October 2026. https://doi.org/10.1002/da.22693 [Link]
  10. Comer JS, et al. A pilot feasibility evaluation of the CALM Program for anxiety disorders in early childhood. Journal of Anxiety Disorders. Published 2012. Accessed October 2026. https://doi.org/10.1016/j.janxdis.2011.08.011 [Link]